Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.
Saunders, Mark P
AffiliationUniversity Cancer Center / Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany
MetadataShow full item record
AbstractThe combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.
CitationOxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study. 2016: Ann Oncol
JournalAnnals of Oncology